E. Meshalkin National Medical Research Center
Novosibirsk, Russia
Location status: Recruiting
NCT Number: NCT05257161
The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence for a difference between the proximal and distal anti-embolic device for the CGuard stent.
Interested in participating?
Request Info45 year–80 year
All sexes
Interventional
Not applicable
Novosibirsk, Russia
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
Other names: Emboshield NAV6™ Embolic Protection System
Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
Other names: Mo.Ma™ proximal cerebral protection device
Time frame: 24-48 hours
Postprocedural acute ischemic lesions (MRI)
Time frame: Intraoperatively, and within 48 hours.
Death, stroke, and MI
Contact information is provided by the study sponsor or research team.
Meshalkin Research Institute of Pathology of Circulation
Network
Independent Randomized Clinical Trial in Carotid Revascularization With MicroNet Covered Stent (CGuard) Comparing Early Neurological Outcomes With Distal EPS Versus Proximal EPS
Acronym: SIBERIA-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03488199
Asymptomatic Patients (Stenosis ≥80%), Patients With Aterosclerotic Carotid Stenosis
Novosibirsk, Russia
View Trial Details